Stock Research for REGN

REGN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

REGN Stock Chart & Research Data

The REGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the REGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


REGN Due diligence Resources & Stock Charts

The REGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View REGN Detailed Price Forecast - CNN Money CNN View REGN Detailed Summary - Google Finance
Yahoo View REGN Detailed Summary - Yahoo! Finance Zacks View REGN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View REGN Trends & Analysis - Trade-Ideas Barrons View REGN Major Holders - Barrons
NASDAQ View REGN Call Transcripts - NASDAQ Seeking View REGN Breaking News & Analysis - Seeking Alpha
Spotlight View REGN Annual Report - CompanySpotlight.com OTC Report View REGN OTC Short Report - OTCShortReport.com
TradeKing View REGN Fundamentals - TradeKing Charts View REGN SEC Filings - Bar Chart
WSJ View Historical Prices for REGN - The WSJ Morningstar View Performance/Total Return for REGN - Morningstar
MarketWatch View the Analyst Estimates for REGN - MarketWatch CNBC View the Earnings History for REGN - CNBC
StockMarketWatch View the REGN Earnings - StockMarketWatch MacroAxis View REGN Buy or Sell Recommendations - MacroAxis
Bullish View the REGN Bullish Patterns - American Bulls Short Pains View REGN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View REGN Stock Mentions - StockTwits PennyStocks View REGN Stock Mentions - PennyStockTweets
Twitter View REGN Stock Mentions - Twitter Invest Hub View REGN Investment Forum News - Investor Hub
Yahoo View REGN Stock Mentions - Yahoo! Message Board Seeking Alpha View REGN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for REGN - SECform4.com Insider Cow View Insider Transactions for REGN - Insider Cow
CNBC View REGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for REGN - OTC Markets
Yahoo View Insider Transactions for REGN - Yahoo! Finance NASDAQ View Institutional Holdings for REGN - NASDAQ


Stock Charts

FinViz View REGN Stock Insight & Charts - FinViz.com StockCharts View REGN Investment Charts - StockCharts.com
BarChart View REGN Stock Overview & Charts - BarChart Trading View View REGN User Generated Charts - Trading View




Latest Financial News for REGN


Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Posted on Tuesday October 23, 2018

Biogen (BIIB), a leading biotechnology company, released its third-quarter earnings on October 23. Biogen surpassed Wall Street analysts’ estimates for EPS and revenues during the quarter. Biogen reported non-GAAP diluted EPS of $7.40 on revenues of ~$3.44 billion.


Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
Posted on Monday October 22, 2018

Bristol-Myers (BMY) is scheduled to report third-quarter earnings on Oct 25.


FDA Approves Asthma Indication for Dupixent® (dupilumab)
Posted on Monday October 22, 2018

TARRYTOWN, N.Y. and PARIS, Oct. 22, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.


Sanofi drug Dupixent wins U.S. FDA approval to treat asthma
Posted on Friday October 19, 2018

France's Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma. Dupixent, co-developed with U.S.-based Regeneron, received approval to treat patients with eosinophilic asthma and those dependent on anti-inflammatory steroids. The drug, a key revenue driver for Sanofi, had worldwide sales of 176 million euros ($202.5 million) in the second quarter of 2018, of which 151 million euros came from the United States.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.